For documented multidrug resistant Gram-negative infections due to organisms proven or suspected to be susceptible to Piperacillin/Tazobactam except CNS infections; and for polymicrobial infections (e.g., mixed aerobic and anaerobic infections in which other agents have insufficient activity or are contraindicated due to toxic potential).